Advertisement

Journal of Neuro-Oncology

, Volume 114, Issue 1, pp 135–140 | Cite as

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

  • Xiaoyin JiangEmail author
  • David A. Reardon
  • Annick Desjardins
  • James J. Vredenburgh
  • Jennifer A. Quinn
  • Alan D. Austin
  • James E. Herndon2nd
  • Roger E. McLendon
  • Henry S. Friedman
Clinical Study

Abstract

Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O6-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized that MGMT immunohistochemistry would predict resistance to temozolomide in PCNSL. A retrospective study of newly-diagnosed and recurrent PCNSL patients treated at our institution was conducted to study the predictive value of MGMT immunohistochemistry for response to temozolomide. 20 patients who were treated with temozolomide as a single agent were identified during the study time period. 6/20 patients demonstrated a response, corresponding to an objective response rate of 30 % (95 % CI 8–52). Five patients with low MGMT level (<30 %) showed a response to temozolomide. Only one of 10 patients (10 %) with high MGMT level (≥30 %) exhibited a response to temozolomide. Small sample numbers precluded formal statistical comparisons. Two patients with complete response remain alive without progressive disease 6.7 and 7.2 years after temozolomide initiation. Immunohistochemistry can be performed on small biopsies to selectively assess MGMT status in tumor versus surrounding inflammation. MGMT analysis by immunohistochemistry may predict response to temozolomide in PCNSL and should be prospectively investigated.

Keywords

Temozolomide MGMT Primary central nervous system lymphoma Chemotherapy Immunohistochemistry 

Notes

Acknowledgments

The authors would like to acknowledge Ms. Debra Fleming and Mrs. Kathryn Perkinson for their technical assistance.

Ethical standards

The described experiments comply with the current laws of the United States.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95(1):193–202PubMedCrossRefGoogle Scholar
  2. 2.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24(8):1281–1288. doi: 10.1200/jco.2005.04.8819 PubMedCrossRefGoogle Scholar
  3. 3.
    Harder H, Holtel H, Bromberg JEC, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, Menten J, van den Bent MJ (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4):544–547PubMedCrossRefGoogle Scholar
  4. 4.
    Mohile NA, Abrey LE (2007) Primary central nervous system lymphoma. Semin Radiat Oncol 17(3):223–229PubMedCrossRefGoogle Scholar
  5. 5.
    Bessell EM, Hoang-Xuan K, Ferreri AJM, Reni M (2007) Primary central nervous system lymphoma—biological aspects and controversies in management. Eur J Cancer 43(7):1141–1152PubMedCrossRefGoogle Scholar
  6. 6.
    DeAngelis LM, Iwamoto FM (2006) An update on therapy of primary central nervous system lymphoma. Hematology 1:311–316. doi: 10.1182/asheducation-2006.1.311 CrossRefGoogle Scholar
  7. 7.
    Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA (2007) Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48(9):1712–1720PubMedCrossRefGoogle Scholar
  8. 8.
    Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2002) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15. J Clin Oncol 21(12):2407–2414. doi: 10.1200/jco.2003.01.135 CrossRefGoogle Scholar
  9. 9.
    Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticancer Ther 7(5):689–700. doi: 10.1586/14737140.7.5.689 PubMedCrossRefGoogle Scholar
  10. 10.
    Panageas Katherine S, EBELB-PLMDLEA (2007) Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 110(6):1338–1344PubMedCrossRefGoogle Scholar
  11. 11.
    Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64(7):1184–1188. doi: 10.1212/01.wnl.0000156350.49336.e2 PubMedCrossRefGoogle Scholar
  12. 12.
    Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703. doi: 10.1634/theoncologist.11-6-694 PubMedCrossRefGoogle Scholar
  13. 13.
    Abrey LE, Correa DD (2005) Treatment-Related Neurotoxicity. Hematol Oncol Clin N Am 19(4):729–738CrossRefGoogle Scholar
  14. 14.
    Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58(10):1573–1574PubMedCrossRefGoogle Scholar
  15. 15.
    Lerro KA, Lacy J (2002) Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59(2):165–168PubMedCrossRefGoogle Scholar
  16. 16.
    Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J (2007) Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma–case report. Neurol Med Chir (Tokyo) 47(5):229–232CrossRefGoogle Scholar
  17. 17.
    Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96(6):864–867. doi: 10.1038/sj.bjc.6603660 PubMedCrossRefGoogle Scholar
  18. 18.
    Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901–903PubMedCrossRefGoogle Scholar
  19. 19.
    Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell’Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40(11):1682–1688PubMedCrossRefGoogle Scholar
  20. 20.
    Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85(2):207–211PubMedCrossRefGoogle Scholar
  21. 21.
    Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12):3851–3857PubMedGoogle Scholar
  22. 22.
    Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi: 10.1056/NEJMoa043331 PubMedCrossRefGoogle Scholar
  23. 23.
    Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97(3):389–392. doi: 10.1007/s11060-009-0032-0 PubMedCrossRefGoogle Scholar
  24. 24.
    Makino K, Nakamura H, Hide T-i, Kuratsu J-i (2012) Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol 106(1):155–160. doi: 10.1007/s11060-011-0652-z PubMedCrossRefGoogle Scholar
  25. 25.
    Quinn JRD, Rich J, et al. (2003) Phase II treatment of adults with newly diagnosed, progressive or recurrent primary central nervous system lymphoma with temodar. Paper presented at the ASCO, Chicago, IllGoogle Scholar
  26. 26.
    McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS (1998) Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 78(5):643–644PubMedGoogle Scholar
  27. 27.
    Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1):139–145. doi: 10.1002/cncr.20339 PubMedCrossRefGoogle Scholar
  28. 28.
    Ohno T, Hiraga J, Ohashi H, Sugisaki C, Li E, Asano H, Ito T, Nagai H, Yamashita Y, Mori N, Kinoshita T, Naoe T (2006) Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 83(4):341–347PubMedCrossRefGoogle Scholar
  29. 29.
    Chu LC, CGESAGJGH (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487–2491PubMedCrossRefGoogle Scholar
  30. 30.
    Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C (2009) MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol 62(8):715–723. doi: 10.1136/jcp.2009.064741 PubMedCrossRefGoogle Scholar
  31. 31.
    Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118(17):4201–4211. doi: 10.1002/cncr.27392 PubMedCrossRefGoogle Scholar
  32. 32.
    Adachi J-i, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R (2012) O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neuro Oncol 107:147. doi: 10.1007/s11060-011-0721-3 CrossRefGoogle Scholar
  33. 33.
    Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043. doi: 10.1200/jco.2005.13.524 PubMedCrossRefGoogle Scholar
  34. 34.
    Mutter N, Stupp R (2006) Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6(8):1187–1204PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Xiaoyin Jiang
    • 1
    Email author
  • David A. Reardon
    • 2
  • Annick Desjardins
    • 3
  • James J. Vredenburgh
    • 4
  • Jennifer A. Quinn
    • 5
  • Alan D. Austin
    • 1
  • James E. Herndon2nd
    • 3
  • Roger E. McLendon
    • 1
  • Henry S. Friedman
    • 3
  1. 1.Department of PathologyDuke University Medical CenterDurhamUSA
  2. 2.Dana-Farber Cancer InstituteBostonUSA
  3. 3.The Preston Robert Tisch Brain Tumor Center at DukeDuke University Medical CenterDurhamUSA
  4. 4.Saint Francis Hospital and Medical CenterHartfordUSA
  5. 5.UNC HospitalChapel HillUSA

Personalised recommendations